Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
Open Access
- 26 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 32 (3), 575-583
- https://doi.org/10.1007/s00198-020-05806-1
Abstract
Summary In postmenopausal osteoporotic women in ACTIVE, abaloparatide reduced fracture risk and increased areal bone mineral density (BMD) more than teriparatide at the hip and wrist. DXA-based 3D modeling showed significantly greater increases in hip cortical volumetric BMD with abaloparatide versus teriparatide. This may explain differences reported in aBMD by DXA. Introduction In ACTIVE, abaloparatide (ABL) increased bone mineral density (BMD) shown by dual-energy X-ray absorptiometry (DXA) while reducing fracture incidence in postmenopausal osteoporotic women. Changes in DXA BMD with ABL, 80 μg, were significantly greater than with open-label teriparatide (TPTD), 20 μg, at cortical sites including total hip, femoral neck, and 1/3 distal radius. The purpose of this study was to better understand the relative effects of ABL and TPTD on cortical and cancellous compartments in the proximal femur. Methods Hip DXA images from a subset of randomly selected patients in the ACTIVE trial (n = 250/arm) were retrospectively analyzed using three-dimensional modeling methods (3D-SHAPER software) to evaluate changes from baseline at months 6 and 18. Results Similar significant increases in trabecular volumetric BMD (vBMD, + 9%) and cortical thickness (+ 1.5%) were observed with ABL and TPTD by 3D-DXA at 18 months. In contrast, only ABL significantly increased cortical vBMD versus baseline (+ 1.3%), and changes in both cortical vBMD and cortical surface BMD were significantly greater with ABL versus TPTD. In the TPTD group, changes in cortical vBMD were inversely correlated with changes in serum CTX (carboxy-terminal telopeptide of type I collagen) and PINP (procollagen type I N-terminal propeptide), suggesting that higher bone turnover may have attenuated cortical gains. Conclusion These results suggest previously reported differences in areal BMD increases between ABL and TPTD may be due to differential effects on cortical vBMD. Further studies are warranted to investigate how these differences affect therapeutic impact on hip strength in postmenopausal women with osteoporosis.Keywords
Funding Information
- Radius Health Inc
This publication has 29 references indexed in Scilit:
- Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosisOsteoporosis International, 2019
- Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modelingOsteoporosis International, 2018
- Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with TeriparatideCalcified Tissue International, 2018
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialThe Lancet, 2017
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisJAMA, 2016
- Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosisBone, 2014
- Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional studyThe Lancet, 2010
- Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structureBone, 2007
- Relation between age, femoral neck cortical stability, and hip fracture riskThe Lancet, 2005
- Teriparatide [PTH(1–34)] Strengthens the Proximal Femur of Ovariectomized Nonhuman Primates Despite Increasing PorosityJournal of Bone and Mineral Research, 2004